| Gene Therapy Press Releases + Feed Topics Locations Industries Dates
 | By Project Alive Parents Trying to Help Fund a Cure For the Rare Disease Hunter Syndrome / MPS II
|  | By Project Alive Parent Efforts Bringing Awareness to the Rare Disease Hunter Syndrome / MPS II
|  | By Aldevron Henry Hebel has been named Chief Operating Officer of Aldevron, a leading global provider of contract plasmid DNA manufacturing, protein production and antibody discovery services.
| By Boston Biotech Meetup Join the Boston Biotech Meetup for Advances in Gene Therapy, an evening of networking, presentations and discussion with local scientists.
|  | By FAST A pioneer on the frontier of genetic medicine and his team at one of the nation's top-five medical research schools have joined forces with FAST (Foundation for Angelman Syndrome Therapeutics) to develop a treatment for the rare disorder Angelman...
|  | By Saving Case & Friends, Inc. Parent-led fundraising efforts have donated over $500,000 to treat the rare disease Hunter Syndrome (MPS II)
|  | By MoBiTec GmbH AUMsilence self-delivering oligos achieve highly efficient and potent antisense-based gene knockdown. No need to use toxic transfection reagents. Especially designed for primary cells and very difficult-to-transfect cell types.
|  | By Saving Case & Friends, Inc. Efforts Bringing Awareness to Hunter Syndrome Are Recognized by Telly Awards and International Songwriting Competition
|  | By Project Alive, a campaign of Saving Case & Friends Parents of children with the rare disease Hunter Syndrome launched a compelling awareness and fundraising campaign with celebrity support including Seattle Seahawks head coach Pete Carroll and radio host Dave Ramsey.
| By Cure SMA Cure SMA, the leading organization dedicated to the treatment and cure of spinal muscular atrophy (SMA), recently provided an additional $445,000 grant toward a gene therapy for SMA at Nationwide Children’s Hospital.
|  | By Mary Ann Liebert, Inc., publishers Contact: Kathryn Ryan, Mary Ann Liebert, Inc., (914) 740-2100, kryan@liebertpub.com Pioneer Award Recipients Robin Ali, PhD, Jean Bennett, MD, PhD, and William Hauswirth, PhD Honored for Their Research on Gene Therapy in Eye Disorders New Rochelle,...
|  | By Mary Ann Liebert, Inc., publishers Contact: Kathryn Ruehle, Mary Ann Liebert, Inc, (914) 740-2100, kruehle@liebertpub.com Splice-Switching Oligonucleotide Therapeutics Is Promising New Method for Editing Gene Transcripts New Rochelle, NY—In splice-switching, an innovative therapeutic...
| | By Mary Ann Liebert, Inc., publishers Contact: Vicki Cohn, Mary Ann Liebert, Inc, (914) 740-2100, ext. 2156, vcohn@liebertpub.com Frederic Bushman, PhD Receives Pioneer Award for Advancing Therapeutic Gene Delivery Methods New Rochelle, NY—Frederic D.
| | By Mary Ann Liebert, Inc., publishers Contact: Vicki Cohn, Mary Ann Liebert, Inc, (914) 740-2100, ext. 2156, vcohn@liebertpub.com James Wilson, MD, PhD Receives Pioneer Award for Research on Gene Therapy and AAV Gene Delivery Systems New Rochelle, NY—James M.
|  | By Mary Ann Liebert, Inc., publishers Marina Cavazzana, MD, PhD, Paris Descartes University, and Adrian J. Thrasher, MD, PhD, University College London Institute of Child Health, have been honored with the Pioneer Award for basic and clinical gene therapy for immunodeficiency disorders.
| | By Mary Ann Liebert, Inc., publishers for Developing First In Vivo Adenoviral Gene Delivery Vector
| | By Mary Ann Liebert, Inc., publishers Contact: Vicki Cohn, Mary Ann Liebert, Inc., (914) 740-2100, ext.
|  | By Mary Ann Liebert, Inc., publishers Contact: Vicki Cohn, Mary Ann Liebert, Inc., (914) 740-2100, ext.
|
All Press Releases
By Mary Ann Liebert, Inc., publishers Researchers used gene transfer to block the expression of one of the two main enzymes that break down alcohol in the liver, leading to the accumulation in liver cells of acetaldehyde, a metabolic byproduct of ethanol.
| | By Project Alive Parents Trying to Help Fund a Cure For the Rare Disease Hunter Syndrome / MPS II
| | By Project Alive Parent Efforts Bringing Awareness to the Rare Disease Hunter Syndrome / MPS II
| | By Aldevron Henry Hebel has been named Chief Operating Officer of Aldevron, a leading global provider of contract plasmid DNA manufacturing, protein production and antibody discovery services.
| By Boston Biotech Meetup Join the Boston Biotech Meetup for Advances in Gene Therapy, an evening of networking, presentations and discussion with local scientists.
| By Mary Ann Liebert, Inc., publishers Researchers are beginning to gain a clearer understanding of how the immune system responds, in both a reactive and tolerant way, to gene therapy delivered using what has become the preferred gene delivery vector, adeno-associated viruses (AAV).
| By Partners4Access Partners4Access Managing Partner Sophie Schmitz attended the World Orphan Drug Congress in Washington and reports insights from the Glybera case.
| By Mary Ann Liebert, Inc., publishers A new study examined 42 combinations of promoters and enhancers for human factor VIII (hFVIII) gene expression to identify the optimal adeno-associated virus (AAV)-based gene therapy delivery vector constructs to take forward into development.
| By Mary Ann Liebert, Inc., publishers Overwhelming evidence from the biomedical literature shows that adeno-associated virus 2 (AAV2), a viral vector often used to deliver therapeutic genes, is not associated with cancer and, in fact, may protect against cancer.
| | By FAST A pioneer on the frontier of genetic medicine and his team at one of the nation's top-five medical research schools have joined forces with FAST (Foundation for Angelman Syndrome Therapeutics) to develop a treatment for the rare disorder Angelman...
| | By Saving Case & Friends, Inc. Parent-led fundraising efforts have donated over $500,000 to treat the rare disease Hunter Syndrome (MPS II)
| By Allied Market Research A new report published by Allied Market Research titled, "Regenerative Medicine Market- Global Opportunity Analysis and Industry Forecast, 2014 - 2022", projects that the global regenerative medicine market would reach $30,237 million by 2022.
| | By MoBiTec GmbH AUMsilence self-delivering oligos achieve highly efficient and potent antisense-based gene knockdown. No need to use toxic transfection reagents. Especially designed for primary cells and very difficult-to-transfect cell types.
| | By Saving Case & Friends, Inc. Efforts Bringing Awareness to Hunter Syndrome Are Recognized by Telly Awards and International Songwriting Competition
| | By Project Alive, a campaign of Saving Case & Friends Parents of children with the rare disease Hunter Syndrome launched a compelling awareness and fundraising campaign with celebrity support including Seattle Seahawks head coach Pete Carroll and radio host Dave Ramsey.
| By Foundation Care Pharmacy Foundation Care Pharmacy, located in Earth City, MO, will be one of the pharmacies to provide cystic fibrosis patients with the new Vertex drug ORKAMBI™ (lumacaftor/ivacaftor).
| By Cure SMA Cure SMA, the leading organization dedicated to the treatment and cure of spinal muscular atrophy (SMA), recently provided an additional $445,000 grant toward a gene therapy for SMA at Nationwide Children’s Hospital.
| By SMi Group Ltd SMi’s BioBanking conference will be taking place on the 22 - 23 June 2015 at the Holiday Inn Regents Park Hotel in London, UK.
| By Delveinsight Business Research LLP DelveInsight a Market Research & Business Consulting firm has started a promotional offer on its Gene therapy reports highlighting their on-going demand across the globe.
| By Visiongain Visiongain’s new report predicts the world stem cell technologies market will reach $7.2bn in 2014. The overall industry will earn $12bn in 2018, achieving high revenue growth from 2015 to 2025.
| By MoBiTec GmbH Experience the transfection breakthrough. Achieve superior transfections with an innovative polymeric system that efficiently delivers both DNA and RNA out of the endosome and into the cytoplasm overcoming a critical barrier to nucleic acid delivery.
| By Delveinsight Business Research LLP Take Advantage of the very lucrative gene therapy market and play in the rare-air of the very few with DelveInsight’s Gene Therapy Reports!
| | By Mary Ann Liebert, Inc., publishers Contact: Kathryn Ryan, Mary Ann Liebert, Inc., (914) 740-2100, kryan@liebertpub.com Pioneer Award Recipients Robin Ali, PhD, Jean Bennett, MD, PhD, and William Hauswirth, PhD Honored for Their Research on Gene Therapy in Eye Disorders New Rochelle,...
| | By Mary Ann Liebert, Inc., publishers Contact: Kathryn Ruehle, Mary Ann Liebert, Inc, (914) 740-2100, kruehle@liebertpub.com Splice-Switching Oligonucleotide Therapeutics Is Promising New Method for Editing Gene Transcripts New Rochelle, NY—In splice-switching, an innovative therapeutic...
| | By Mary Ann Liebert, Inc., publishers Contact: Vicki Cohn, Mary Ann Liebert, Inc, (914) 740-2100, ext. 2156, vcohn@liebertpub.com Frederic Bushman, PhD Receives Pioneer Award for Advancing Therapeutic Gene Delivery Methods New Rochelle, NY—Frederic D.
| | By Mary Ann Liebert, Inc., publishers Contact: Vicki Cohn, Mary Ann Liebert, Inc, (914) 740-2100, ext. 2156, vcohn@liebertpub.com James Wilson, MD, PhD Receives Pioneer Award for Research on Gene Therapy and AAV Gene Delivery Systems New Rochelle, NY—James M.
| | By Mary Ann Liebert, Inc., publishers Marina Cavazzana, MD, PhD, Paris Descartes University, and Adrian J. Thrasher, MD, PhD, University College London Institute of Child Health, have been honored with the Pioneer Award for basic and clinical gene therapy for immunodeficiency disorders.
| By Mary Ann Liebert, Inc., publishers Contact: Jennifer Quigley, Mary Ann Liebert, Inc, (914) 740-2100, ext.
| By Mary Ann Liebert, Inc., publishers Contact: Vicki Cohn, Mary Ann Liebert, Inc, (914) 740-2100 (914) 740-2100, ext. 2156, vcohn@liebertpub.com Joseph Glorioso, PhD Receives Pioneer Award for Engineering Herpes Simplex Virus Gene Delivery Systems New Rochelle, NY—Joseph C.
| | By Mary Ann Liebert, Inc., publishers for Developing First In Vivo Adenoviral Gene Delivery Vector
|
Page updated every 10 minutes
| |
